(12) **Translation of European patent specification**

(11) **NO/EP 3271365 B1**

**NORWAY**

(19) NO

(51) Int Cl.

***C07D 495/04 (2006.01)***

***A61K 31/407 (2006.01)***

**Norwegian Industrial Property Office**

| | | |
|---|---|---|
| (45) | Translation Published | 2020.03.30 |
| (80) | Date of The European Patent Office Publication of the Granted Patent | 2019.12.18 |
| (86) | European Application Nr. | 16714004.5 |
| (86) | European Filing Date | 2016.03.15 |
| (87) | The European Application's Publication Date | 2018.01.24 |
| (30) | Priority | 2015.03.20, US, 201562136223 P<br>2015.03.26, US, 201562138505 P |
| (84) | Designated Contracting States: | AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR |
| (73) | Proprietor | Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA |
| (72) | Inventor | MADERNA, Andreas, 1981 Woodland Heights Glen, Escondido, CA 92026, USA<br>SUBRAMANYAM, Chakrapani, 314 Great Pond Road, South Glastonbury, Connecticut 06073, USA<br>TUMEY, Lawrence N., 37 William Street, Pawcatuck, Connecticut 06379, USA<br>CHEN, Zecheng, 2 Westgate Boulevard, New City, New York 10956, USA<br>CASAVANT, Jeffrey M., 89 Eager Road, Franklin, Connecticut 06254, USA |
| (74) | Agent or Attorney | ZACCO NORWAY AS, Postboks 2003 Vika, 0125 OSLO, Norge |


(54) Title **BIFUNCTIONAL CYTOTOXIC AGENTS CONTAINING THE CTI PHARMACOPHORE**

(56) References Cited:

WO-A2-2011/054837, US-A1- 2009 118 349, WO-A1-2013/149946

MARK S. TICHENOR ET AL: "Rational Design, Synthesis, and Evaluation of Key Analogues of CC-1065 and the Duocarmycins", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 129, no. 45, 1 November 2007 (2007-11-01), pages 14092-14099, XP55042781, ISSN: 0002-7863, DOI: 10.1021/ja073989z

MURATAKE H ET AL: "PREPARATION OF BENZENE, FURAN AND THIOPHENE ANALOGS OF DUOCARMYCIN SA EMPLOYING A NEWLY-DEVISED PHENOL-FORMING REACTION", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, JP, vol. 48, no. 10, 1 January 2000 (2000-01-01), pages 1558-1566, XP001026369, ISSN: 0009-2363

SCHWARTZ G H ET AL: "A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies", ANNALS OF ONCOLOGY, KLUWER, DORDRECHT, NL, vol. 14, no. 5, 1 May 2003 (2003-05-01), pages 775-782, XP002624233, ISSN: 0923-7534, DOI: 10.1093/ANNONC/MDG215

**Patentkrav**

**1.** Forbindelse eller et farmasøytisk akseptabelt salt eller solvat derav, valgt fra:


,


,


,


,




,




,




,




og




,

der Pg er H, acyl, $PO_3H_2$ eller glykosyl.

**2.** Forbindelse eller et farmasøytisk akseptabelt salt eller solvat derav, valgt fra:



**3.** Forbindelse eller et farmasøytisk akseptabelt salt eller solvat derav, valgt fra:















5









5











og



der AB er et antistoff.

**4.** Forbindelsen ifølge krav 3 eller et farmasøytisk akseptabelt salt eller solvat derav, hvori antistoff AB er valgt fra trastuzumab, trastuzumabmutanter, oregovomab, edrecolomab, cetuximab, et humanisert monoklonalt antistoff mot vitronectinreseptoren (αvβ3), alemtuzumab, anti-HLA DR-antistoffer, 131I Lym 1, anti-HLA-Dr10-antistoffer, anti-cd33-antistoffer, anti-cd22-antistoffer, labetuzumab, bevacizumab, ibritumomab-tiuxetan, ofatumumab, panitumumab, rituximab, tositumomab, ipilimumab og gemtuzumab.

**5.** Forbindelse ifølge krav 3 eller et farmasøytisk akseptabelt salt eller solvat derav, valgt fra:



hvori X er et antistoff valgt fra gruppen bestående av IL13Rα2-AB08-v1.0, CD33-11A1-v1417-hG1-(C), CD33-11A1-v1417-K334C-K392C-hG1-(C334+C392) og CD33-11A1-v1417-K334C-hG1-(C334).

**6.** Linker-payload eller et antistofflegemiddelkonjugat eller et farmasøytisk akseptabelt salt eller solvat derav, omfattende et radikal av en forbindelse ifølge krav 1.

**7.** Antistofflegemiddelkonjugat eller et farmasøytisk akseptabelt salt eller solvat derav, omfattende et radikal av en forbindelse ifølge krav 2.

**8.** Farmasøytisk sammensetning omfattende en forbindelse ifølge et hvilket som helst av kravene 1 til 7, eller et farmasøytisk akseptabelt salt eller solvat derav, og en farmasøytisk akseptabel eksipient.

**9.** Forbindelse ifølge et hvilket som helst av kravene 1 til 7 eller et farmasøytisk akseptabelt salt eller solvat derav eller en farmasøytisk sammensetning ifølge krav 8, for anvendelse i behandling av kreft.

**10.** Forbindelse eller et farmasøytisk akseptabelt salt eller solvat derav eller en farmasøytisk sammensetning for anvendelse ifølge krav 9, hvori kreften er blærekreft, brystkreft, livmorhalskreft, tykktarmskreft, endometriekreft, nyrekreft, lungekreft, spiserørskreft, eggstokkreft, prostatakreft, bukspyttkjertelkreft, hudkreft, mage- (gastrisk) kreft, testikkelkreft, leukemier og lymfomer.